Evaluation of an Assay for MGMT Gene Promoter Methylation in Glioblastoma Samples.
Anticancer Res
; 40(11): 6229-6236, 2020 Nov.
Article
en En
| MEDLINE
| ID: mdl-33109560
ABSTRACT
BACKGROUND/AIM:
To compare the GeneXpert® O6-methylguanine DNA methyltransferase (MGMT) methylation prototype (GX MGMT) assay with pyrosequencing in glioblastomas. MATERIALS ANDMETHODS:
The MGMT methylation status was retrospectively assessed in formalin-fixed paraffin embedded (FFPE) tumor blocks from 262 glioblastoma patients obtained from three independent cohorts using either a standard of care pyrosequencing laboratory developed test or the GX MGMT assay.RESULTS:
The concordance rate was 92.1% (58/63) for Oregon Health and Science University (OSHU) samples, 91.7% (88/96) for Medical University of Vienna (MUV) samples, and 82.5% (85/103) for Kepler University Hospital (KUH) samples. Patients with MGMT promoter hypermethylation assessed by pyrosequencing or the GX MGMT test had a significantly longer overall survival compared to patients without hypermethylation (HR=0.43, 95%CI=0.26-0.72, p=0.001 and HR=0.51, 95%CI=0.31-0.84, p=0.008, respectively).CONCLUSION:
Standardized, simplified, and on-demand testing of MGMT promoter methylation by the GX MGMT assay is feasible.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Bioensayo
/
Neoplasias Encefálicas
/
Metilasas de Modificación del ADN
/
Reacción en Cadena de la Polimerasa
/
Regiones Promotoras Genéticas
/
Glioblastoma
/
Metilación de ADN
/
Proteínas Supresoras de Tumor
/
Enzimas Reparadoras del ADN
Tipo de estudio:
Evaluation_studies
Límite:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Child
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Anticancer Res
Año:
2020
Tipo del documento:
Article
País de afiliación:
Austria